Literature DB >> 6386481

Prevention of thromboembolic complications with miniheparin-dihydroergotamine in patients undergoing lumbar disc operations.

U F Gruber, J Rem, C Meisner, O Gratzl.   

Abstract

We have evaluated the incidence of bleeding complications using miniheparin (2 X 2500 IU daily)-dihydroergotamine starting preoperatively in a randomized, controlled, prospective, double-blind study in 50 patients undergoing herniated lumbar disc operations. There was no difference in the incidence of intraoperative bleeding problems between the two groups. Preoperatively, 13 patients have been treated in another hospital with conventional low-dose heparin, and of these 13 patients, 7 developed bleeding complications. There were two deep wound hematomas in the placebo group. Early removal of stitches or operative revision of the wound was not necessary in either group. We conclude that the use of minidose heparin-dihydroergotamine is feasible for the prevention of thromboembolic complications in patients undergoing herniated lumbar disc operations, since an increased incidence of bleeding complications was not observed. This preventive method should therefore be further clinically evaluated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386481     DOI: 10.1007/bf00461554

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  11 in total

1.  Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors.

Authors:  O Havig
Journal:  Acta Chir Scand Suppl       Date:  1977

2.  Safety of mini-dose heparin administration for neurosurgical patients.

Authors:  H G Barnett; J R Clifford; R C Llewellyn
Journal:  J Neurosurg       Date:  1977-07       Impact factor: 5.115

3.  [Thromboembolism prophylaxis with reduced bleeding risk. Trials with heparin-dihydroergot 2500].

Authors:  K Koppenhagen; R Häring
Journal:  Med Welt       Date:  1981-06-19

4.  A new sequential pneumatic device for the prevention of deep vein thrombosis.

Authors:  A Zelikovski; G Zucker; A Eliashiv; R Reiss; M Shalit
Journal:  J Neurosurg       Date:  1981-05       Impact factor: 5.115

5.  Heparin aerosol - effect on blood coagulation and pulmonary function.

Authors:  M Hellgren; K Hägnevik; M Blombäck
Journal:  Thromb Res       Date:  1981 Feb 15-Mar 1       Impact factor: 3.944

6.  [The risk of hemorrhaging in the prevention of thromboembolism in general surgery: comparison of low-dose heparin and heparin-dihydergot 2500].

Authors:  J F Ammann; B Aebi
Journal:  Chirurg       Date:  1983-01       Impact factor: 0.955

7.  Prophylaxis of thromboembolism in the neurosurgical patient: a review.

Authors:  S K Powers; M S Edwards
Journal:  Neurosurgery       Date:  1982-04       Impact factor: 4.654

8.  Dihydroergotamine and heparin or heparin alone for the prevention of postoperative thromboembolism in gynecology.

Authors:  M K Hohl; K P Lüscher; M Annaheim; R Fridrich; U F Gruber
Journal:  Arch Gynecol       Date:  1980

9.  [Perispinal anesthesia and subcutaneous administration of low-dose heparin-dihydergot for prevention of thromboembolism].

Authors:  B H Allemann; H Gerber; U F Gruber
Journal:  Anaesthesist       Date:  1983-02       Impact factor: 1.041

10.  Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients.

Authors:  D Cerrato; C Ariano; F Fiacchino
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

View more
  7 in total

1.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Michael K Gould; David A Garcia; Sherry M Wren; Paul J Karanicolas; Juan I Arcelus; John A Heit; Charles M Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism.

Authors:  Juan José Yepes-Nuñez; Anita Rajasekhar; Maryam Rahman; Philipp Dahm; David R Anderson; Luis Enrique Colunga-Lozano; Stephanie Ross; Meha Bhatt; Kelly Estrada Orozco; Federico Popoff; Matthew Ventresca; Angela M Barbara; Sara Balduzzi; Housne Begum; Arnav Agarwal; Wojtek Wiercioch; Robby Nieuwlaat; Gian Paolo Morgano; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-06-23

Review 3.  Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis.

Authors:  Nasser Alshehri; David J Cote; M Maher Hulou; Ahmad Alghamdi; Ali Alshahrani; Rania A Mekary; Timothy R Smith
Journal:  J Neurooncol       Date:  2016-09-03       Impact factor: 4.130

4.  Deep venous thrombosis in spine surgery patients: incidence and hematoma formation.

Authors:  Thair M Al-Dujaili; Catalin N Majer; Tarek E Madhoun; Sebouh Z Kassis; Alaa A Saleh
Journal:  Int Surg       Date:  2012 Apr-Jun

5.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Authors:  David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm
Journal:  Blood Adv       Date:  2019-12-10

6.  Is chemical antithrombotic prophylaxis effective in elective thoracolumbar spine surgery? Results of a systematic review.

Authors:  James M Schuster; Dena Fischer; Joseph R Dettori
Journal:  Evid Based Spine Care J       Date:  2010-08

7.  Thromboprophylaxis in elective spinal surgery: A protocol for systematic review.

Authors:  María J Colomina; Joan Bagó; Javier Pérez-Bracchiglione; Maria Betina Nishishinya Aquino; Karla R Salas; Carolina Requeijo; Gerard Urrútia
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.